Practical workshops

Emma Wilmot

Emma Wilmot is Consultant Diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust and Honorary (consultant) Assistant Professor, University of Nottingham.

Dr Wilmot’s specialist interests include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care.

Dr Wilmot is chair of the ABCD Diabetes Technology Network UK. In this role she leads the delivery of a program of educational events for multidisciplinary diabetes teams. She has led the development of a suite of national ‘best practice’ guides related to insulin pump therapy and is a member of the National Diabetes Audit Insulin Pump Expert Reference Group, developing the 2018 national Type 1 diabetes service level audit. Dr Wilmot has been involved in the #language matters movement which aims to improve healthcare professional communication with people with diabetes.

Dr Wilmot was awarded the University of Leicester medal for excellent PhD performance in 2013 for her PhD “Type 2 diabetes in younger adults”.

Disclosures

Personal fees from Abbott Diabetes Care, Dexcom, Diasend, Eli Lilly, Medtronic, Novo Nordisk, Sanofi Aventis.

Stephanie Amiel

Stephanie Amiel is professor of diabetes research at Kings College, London, UK. She is an experimental medicine researcher with interests in the prevention and management of hypoglycemia in diabetes treatments and the role of the brain in control of metabolism. She also conducts research in the impact of ethnicity on metabolism. Professor Amiel trained at Guy’s Hospital with Professor Harry Keen and started her research career at Yale, with Professors Robert Sherwin and William Tamborlane. She led the King’s team in a collaboration with Sheffield and North Tyneside in the creation of DAFNE, the UK’s first national structured education program in flexible insulin therapy for adults with type 1 diabetes and continues to research in the area. With colleagues in the King’s Liver Unit, she set up the King’s human islet isolation and transplantation service and has developed services at King’s College Hospital NHS Foundation Trust for supporting adults with Type 1 diabetes and pregnancy in diabetes.

Her current research includes neuroimaging to investigate the role of the brain in hypoglycemia defenses in type 1 diabetes and in appetite control in insulin resistance and she is currently running the HARPdoc randomized controlled trial of a novel intervention for treatment-resistant hypoglycemia in adults with type 1 diabetes, looking at the impact of cognitions on hypoglycemia avoidance behaviors. Professor Amiel was awarded the Banting Memorial Lecture of Diabetes UK, the highest award bestowed by the charity, in 2013. She chaired the Guideline Development Group for the diagnosis and management of type 1 diabetes in adults, published in 2015, and currently chairs the Strategic Research Advisory Group for Diabetes UK and is a mentor on the EFSD Mentorship program.

Disclosures

Received grants/research support or honoraria/consultation fees from Novo Nordisk, Medronic and Roche.

Simon Heller

Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust.

He trained in clinical diabetes at Queen’s Medical Centre, Nottingham and in research at the University of Nottingham and Washington University, St Louis, USA.  He was Editor of Diabetic Medicine from 2000-2005.  He is currently the National Speciality Lead in Diabetes to the NIHR Clinical Research Network and an NIHR Senior Investigator. He is a former member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and chairs the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee. 

He chairs the International Hypoglycaemia Study group, an independently funded group of international experts with research and clinical expertise in hypoglycaemia.  The group has a remit to reduce the burden of hypoglycemia though educational activities.

He chaired the glucose control group of the ADVANCE trial, is a steering committee member of the EXAMINE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps.

His research interests include the pathophysiological responses to hypoglycemia and hypoglycemia unawareness, the potential contribution and mechanisms of hypoglycemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycemia.  He also conducts research concerned with developing programs (including the DAFNE intervention) to encourage more effective diabetes self-management.  He has authored over 200 original research articles and reviews.

Disclosures

Advisory Board Member for Eli Lilly, Novo Nordisk, Sanofi Aventis, Takeda, Zealand Pharma, UN-EEG and Boehringer Ingelheim. Consultant for Eli Lilly and Novo Nordisk. On the Speaker’s Bureau for Eli Lilly and Novo Nordisk.

Personalizing treatment for a variable lifestyle

Upon successful completion of this activity, learners will be able to:

1. Identify the underlying behavioral and psychological issues associated with problematic hypoglycemia.
2. Utilize effective communication skills that can lead to improved adherence and patient self-management behaviors.

A case of severe hypoglycemia unawareness

Upon successful completion of this activity, learners will be able to:

1. Identify the underlying behavioral, cognitive and psychological issues associated with problematic hypoglycemia.
2. Utilize effective communication skills that can lead to improved adherence and patient self-management behaviors.